Turnstone Biologics Acquires Myst Therapeutics

Bristol Myers Squibb Acquires Turning Point Therapeutics

June 3, 2022

Biotechnology

Bristol Myers Squibb agreed to acquire clinical-stage precision oncology company Turning Point Therapeutics in an all-cash transaction valuing the company at approximately $4.1 billion ($76.00 per share). The deal adds Turning Point's lead asset, repotrectinib, and its precision oncology pipeline to BMS's oncology franchise and is expected to close in 2022 (tender offer completed and merger subsequently closed).

Millstone Medical Outsourcing Acquires MycoScience

November 14, 2022

Healthcare Services

Millstone Medical Outsourcing, an Arlington Capital Partners portfolio company, has completed the acquisition of MycoScience, a Willington, Connecticut-based provider of medical device and pharmaceutical laboratory and environmental testing services. The acquisition adds advanced laboratory and regulatory testing capabilities to Millstone's post-manufacturing and aftermarket services, enabling more in-house testing, faster time to market, and expanded end-to-end offerings.

Treadwell Therapeutics Acquires TCRyption Inc.

October 15, 2021

Biotechnology

Treadwell Therapeutics announced it has acquired TCRyption Inc., a TIO Bioventures–backed developer of a novel TCR-identification platform for T cell therapies, in a stock-swap transaction. The acquisition brings the TCRypt platform and a bank of TCR candidates into Treadwell's pre-clinical oncology pipeline to expand its cell-therapy capabilities, with initial TCR programs expected to enter the clinic in early 2023.

Taconic Biosciences Acquires TransCure bioServices

January 20, 2026

Biotechnology

Taconic Biosciences has acquired TransCure bioServices SAS to create an integrated global translational research platform combining Taconic's genetically engineered and humanized mouse models with TransCure's preclinical in vivo services. The deal expands Taconic's capabilities across oncology, immunology, infectious disease, and advanced modalities while preserving TransCure's brand and operational structure to ensure continuity for employees and clients.

Xcovery Acquires Majority Controlling Stake in Meryx Pharmaceuticals

December 7, 2021

Pharmaceuticals

Xcovery Holdings, an oncology-focused biopharmaceutical company, has acquired a majority and controlling stake in Meryx, Inc., a clinical-stage immuno-oncology company based in Chapel Hill, North Carolina. The deal aims to accelerate Meryx's clinical and preclinical drug development programs for small-molecule oncology therapies, with strategic support noted from Betta Pharmaceuticals; financial terms were not disclosed.

Eclipsebio Acquires Terrain Bio

January 29, 2026

Biotechnology

Eclipse Bioinnovations (Eclipsebio) has acquired Terrain Bio to integrate Terrain's AI/ML RNA design models and R&D-scale mRNA manufacturing analytics into Eclipsebio's sequencing-based validation platforms. The deal creates an end-to-end Design, Make, Test platform intended to accelerate RNA therapeutic development by connecting computational design directly to experimental feedback.